Brief: Cytrx reports Q1 loss per share $0.10

LadRx

10/05/2017 14:00

May 10 (Reuters) - Cytrx Corp  CYTR.O  
    * Cytrx reports first quarter 2017 financial results 
    * Q1 loss per share $0.10 
    * Cytrx corp - goal is to submit a rolling nda under section 
505(b)(2) to FDA in Q4 of 2017 for aldoxorubicin 
    * Cytrx Corp- commercial launch of aldoxorubicin is 
projected for 2018 in U.S 
    * Cytrx Corp - Cytrx also plans to discuss with European 
Medicines Agency a path to filing a marketing authorization 
application. For aldoxorubicin 
 
Source text for Eikon:  ID:nPn7fNGLfa  
Further company coverage:  CYTR.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))